<DOC>
	<DOCNO>NCT00853151</DOCNO>
	<brief_summary>Test safety , tolerability improvement blood sugar control combination therapy individual Type 2 Diabetes .</brief_summary>
	<brief_title>A Study Test Combination Two Different Kinds Medications Treatment Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Written inform consent Have type 2 diabetes mellitus ( T2DM ) least 6 month Currently treat diet exercise alone combination stable metformin Glycosylated hemoglobin ( HbA1c ) 7.0 % 10.0 % Ages 18 70 year Women childbearing potential Body mass index ( BMI ) 25 40 kilogram per meter square ( kg/m^2 ) , stable weight 3 month prior screen . Use diabetes medicine metformin past 3 month Gastrointestinal disease surgery drug significantly impact gastric filling , empty motility ; ongoing cholelithiasis cholecystitis . Chronic , daily proton pump inhibitor ( PPIs ) histamine ( H2 ) antagonists . Severe hypoglycemia hyperglycemia Advanced microvascular diabetes complication Medications promote weight loss . Breastfeeding woman Cardiac autonomic neuropathy In past 6 month cardiac disease functional status Class IIIV history myocardial infarction , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , transient ischemic attack , cerebrovascular accident ( stroke ) , decompensated congestive heart failure . History supraventricular ventricular tachycardia , pacemaker implantation , cardiac arrhythmia : Poorly control hypertension , malignant hypertension , renal artery stenosis , and/or evidence labile blood pressure include symptomatic postural hypotension . Electrocardiograms ( ECG ) abnormality medication impair ability measure QT interval ( QT ) , correct QT interval ( QT ) rate . QT interval Bazett correct ( QTcB ) &gt; 450 millisecond ( msec ) PR interval ( PR ) &gt; 220 millisecond ( msec ) Personal family history long QT interval ( QT ) syndrome , sudden death , unexplained syncope Clinical sign symptoms liver disease , acute chronic hepatitis , alanine transaminase level &gt; 2.5 time upper limit reference range Hypertriglyceridemia &gt; 400 mg/deciliter ( dL ) Inadequately treat hypothyroidism hyperthyroidism Peptic ulcer disease and/or gastrointestinal bleeding/perforation . Known pentagastrin hypersensitivity Impaired renal function Transplanted organ . Active , uncontrolled endocrine autoimmune abnormality &gt; 2 week systemic glucocorticoid therapy Ongoing course nonsteroidal antiinflammatory drug ( NSAIDs ) , except aspirin 81325 milligram ( mg ) Diagnosed malignancy remission le 5 year . Prior acute chronic pancreatitis elevate serum lipase amylase Current central nervous system stimulant Other condition preclude participant participating , follow complete protocol . Chronic infection Personnel affiliate study immediate family . Within 30 day initial dose study drug , participate interventional medical , surgical , pharmaceutical study medical surgical treatment give . Have previously complete withdrawn study provide informed consent . Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>